liminal biosciences inc., a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel treatments for patients suffering from diseases that have unmet medical needs. it operates through two segments, small molecule therapeutics and plasma derived therapeutics. the small molecule therapeutics segment's lead product candidate is fezagepras (pbi-4050) for the treatment of idiopathic pulmonary fibrosis, respiratory diseases, and alstrã¶m syndrome. the plasma derived therapeutics segment provides plasma protein purification system, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. it also engages in developing ryplazim for the treatment of congenital plasminogen deficiency. the company operates in canada, the united kingdom, and the united states. the company was formerly known as prometic life sciences inc. and changed its name to liminal biosciences inc. in october